8:30am ET
Investing
UBS Makes Changes to Quality Growth at a Reasonable Price Stock List
In a new report, UBS updates its list of quality growth at a reasonable price, or Q-GARP, stocks as they call them.
Companies
Mylan Inc.
$15.86
â–² $0.00 (+0.00%) today
Markets open · 11:39am ET
MYL Coverage
Page 9
8:25am ET
Investing
Top Analyst Upgrades and Downgrades: Celgene, Enterprise, Meritage, Mobileye, Qlik and More
These are the top analyst upgrades, downgrades and initiations covered by 24/7 Wall St. on Monday, October 6, 2014.
1:30pm ET
Investing
Is Treasury Plan for Tax Inversion REALLY Trouble for Merger Stocks?
The U.S. Treasury has finally made its proposed effort to deal with the waves of corporate tax inversions that have created such a stir of late.
8:40am ET
Investing
Top Analyst Upgrades and Downgrades: ABB, BofA, J.P. Morgan, SanDisk, Micron, Mylan and More
These are the top analyst upgrades and downgrades from 24/7 Wall St. for Wednesday, September 3, 2014.
8:34am ET
Investing
Top Analyst Upgrades and Downgrades: Zynga, Barrick, Allergan, BioCryst, Mylan, NVIDIA and More
Jon OggStocks turned green on Friday morning on hopes out of Russia, but the markets have remained at risk. Now that investors have an opportunity to look for stocks that have pulled…
8:50am ET
Investing
Top Analyst Upgrades and Downgrades: Amazon, Brightcove, Exxon, GM, Mylan, Petrobras, Twitter and Many More
These are this Friday's top analyst upgrades, downgrades and initiations from Wall Street firms on Friday, July 25, 2015. They include Amazon.com, Brightcove, Exxon, GM, Mylan, Petrobras and Twitter.
8:45am ET
Investing
Top Analyst Upgrades and Downgrades: DuPont, GE, King, Microsoft, Xilinx, McDonald’s and More
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Wednesday, July 23, 2014. They include DuPont, General Electric, King, Microsoft, Xilinx and McDonald's.
10:40am ET
Health and Healthcare
Abbott, Mylan Join Forces to Dodge U.S. Taxes
Add one more to the litany of pharmaceutical company mergers that are being made to avoid U.S. taxes. Mylan's existing business with part of Abbott's generic drug business.
7:30am ET
Health and Healthcare
Mylan Falls Short on Revenues, Hints at Acquisition to Come
Mylan reported first-quarter 2014 results before markets opened Thursday. The generic drug maker reaffirmed its full-year EPS guidance and hinted at an acquisition by the end of the year.
Trey Thoelcke 10:35am ET
Health and Healthcare
Meda Shareholder Blocks Mylan’s Second Takeover Bid
Shares of Mylan retreated first thing Monday morning, after the generic drugmaker's sweetened bid for Swedish drugmaker Meda was rejected.
Trey Thoelcke 9:05am ET
Health and Healthcare
J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside
In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off that may provide investors some incredible outsized gains over the rest of…
9:50am ET
Investing
Five Stocks That Have Fallen Most With the Lowest P/E Ratios
In a new report, RBC has a list of stocks with some of the largest percentage drops and the lowest forward price-to-earnings (P/E) ratios. This may serve as shopping list for the…
12:50pm ET
Health and Healthcare
Teva’s Latest Victory in Effort to Protect Key Patents
Teva Pharmaceutical shares reached a new multiyear high Monday after the U.S. Supreme Court agreed to hear its appeal to revive a patent on its top-selling multiple-sclerosis drug.
8:45am ET
Health and Healthcare
J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now
Wikimedia CommonsWith the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large biotechnology stocks were not the lone rangers when it came to the…
11:05am ET
Health and Healthcare
Why Teva May Be Back From the Dead
Two analyst upgrades on Friday, a new CEO and a 33% increase in its stock price since November may be confirmation that Teva Pharmaceutical Industries is finally rebounding. Analysts think the stock…
